Literature DB >> 9605966

Hepatic fibrosis as wound repair: a progress report.

D M Bissell1.   

Abstract

The injury response of the liver fits within the general paradigm of wound repair. The overall repair response requires close coordination of several cell types and synthetic processes and is orchestrated by an interacting group of cytokines, extracellular matrix (ECM) proteins, and products of metabolism such as oxygen radicals. Many cytokines act over short distances, engaging specific receptors on their parent cell (autocrine) or on immediately adjacent cells (paracrine). The most prominent of these is transforming growth factor-beta (TGFbeta). The ECM also mediates cellular crosstalk and does so in two ways. Firstly, as a binder of cytokines, it is capable of concentrating, presenting, or sequestering these factors at specific locations. Secondly, like cytokines, individual ECM proteins interact with cells via specific receptors, many of which belong to the integrin family. Engagement of a receptor leads to its activation, followed by intracellular signaling events and modification of cell behavior. Recent work has identified a specific integrin on stellate cells (alpha1beta1) as critical to the contractility of these cells. Finally, contrary to the view once held of ECM as relatively inert "ground substance", this extracellular complex is highly dynamic, its cytokine- and cell-binding activities being subject to rapid change. Therefore, matrix proteinases also are important, both during the initiation of fibrosis in association with stellate cell activation, and during the resolution of the injury. As current research reveals the key elements of this regulatory network, new therapeutic modalities are emerging. The goal of therapy is to modify the extent of the repair response without deleting it. Strategies directed at several levels of regulation are under consideration, including agents that block cytokine effects (e.g., TGFbeta receptor antagonists) and direct inhibitors of stellate cell activation or contraction.

Entities:  

Mesh:

Year:  1998        PMID: 9605966     DOI: 10.1007/s005350050087

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  29 in total

Review 1.  Advances in gene therapy of liver cirrhosis: a review.

Authors:  W J Dai; H C Jiang
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

2.  Regulation of E-box DNA binding during in vivo and in vitro activation of rat and human hepatic stellate cells.

Authors:  K J Vincent; E Jones; M J Arthur; D E Smart; J Trim; M C Wright; D A Mann
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

3.  Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle.

Authors:  Yong Li; Johnny Huard
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

Review 4.  The pancreatic stellate cell: a star on the rise in pancreatic diseases.

Authors:  M Bishr Omary; Aurelia Lugea; Anson W Lowe; Stephen J Pandol
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

5.  Fibronectin-α4β1 interactions in hepatic cold ischemia and reperfusion injury: regulation of MMP-9 and MT1-MMP via the p38 MAPK pathway.

Authors:  S Duarte; X-D Shen; C Fondevila; R W Busuttil; A J Coito
Journal:  Am J Transplant       Date:  2012-07-19       Impact factor: 8.086

6.  Expression of the integrin alpha8beta1 during pulmonary and hepatic fibrosis.

Authors:  D Levine; D C Rockey; T A Milner; J M Breuss; J T Fallon; L M Schnapp
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

7.  Ca²⁺/calmodulin-dependent protein kinase II mediates platelet-derived growth factor-induced human hepatic stellate cell proliferation.

Authors:  An Ping; Tian Yihao; Dai Jingxing; Chen Minkai; Luo Hesheng
Journal:  Dig Dis Sci       Date:  2012-01-04       Impact factor: 3.199

8.  The antioxidant (-)-epigallocatechin-3-gallate inhibits activated hepatic stellate cell growth and suppresses acetaldehyde-induced gene expression.

Authors:  Anping Chen; Li Zhang; Jianye Xu; Jun Tang
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

9.  KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro.

Authors:  Ping An; Jun-Yong Zhu; Yan Yang; Peng Lv; Yi-Hao Tian; Ming-Kai Chen; He-Sheng Luo
Journal:  World J Gastroenterol       Date:  2007-03-07       Impact factor: 5.742

10.  Curative propensity of green tea extract towards hepatic fibrosis induced by CCl(4): A histopathological study.

Authors:  A M Safer; M Afzal; A Nomani; O Sosamma; S A Mousa
Journal:  Exp Ther Med       Date:  2012-03-02       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.